The CMA has secured the disqualification of a pharmaceutical company director, in connection with his involvement in illegal anti-competitive practices
Pritesh Sonpal – a former director of the pharmaceutical wholesaler Lexon – will be disqualified from taking up any director role or being involved in the management of any company based in England, Scotland or Wales for 4 years.
This move follows the Competition and Markets Authority’s (CMA) decision in March 2020, which found that Lexon – along with the pharmaceutical companies King Pharmaceuticals and Alissa Healthcare Research – illegally shared commercially sensitive information about the antidepressant nortriptyline. As a result, Lexon was fined £1.2 million for breaking competition law.
Nortriptyline is an NHS prescribed drug used by thousands of patients to relieve the symptoms of depression. Between 2015 and 2017, when the cost of the drug was falling, the three suppliers exchanged information about prices, the volumes they were supplying and Alissa’s plans to enter the market, in order to reduce competition.
Lexon subsequently appealed against the CMA’s decision, but in February 2021 the Competition Appeal Tribunal (CAT) upheld it in full.
In connection with Mr Sonpal’s involvement in Lexon’s illegal information sharing, the CMA applied to the court seeking his disqualification as a company director. Mr Sonpal has now accepted the CAT’s findings that his actions caused Lexon to participate in the illegal exchange of sensitive commercial information.
Michael Grenfell, Executive Director of Enforcement at the CMA, said:
The CMA has issued a range of guidance to help businesses and directors understand more about how to comply with competition law, including compliance advice for company directors on how to avoid director disqualification and the competition law risk guide.
Notes to Editors